Alpha 1-antitrypsin deficiency in patients with chronic obstructive pulmonary disease patients: is systematic screening necessary?

Cláudia Henrique da Costa1,2*, Arnaldo José Noronha Filho1,2, Rosa Maria Fernambel Marques e Silva1, Thaís Ferrari da Cruz1, Valeria de Oliveira Monteiro1, Margareth Pio1 and Rogério Lopes Rufino1,2

Abstract

Objective: Alpha-1-antitrypsin deficiency is a relatively prevalent, but under-diagnosed, genetic disease. The objective of this study was to assess whether the systematic screening for alpha-1-antitrypsin deficiency in all patients with chronic obstructive pulmonary disease from a tertiary service has an impact on the number of patients being diagnosed with this condition.

Results: Chronic obstructive pulmonary disease patients were screened for alpha-1-antitrypsin deficiency using immunonephelometry. The presence of a mutation was confirmed by molecular study of the SERPINA1 gene or by genetic sequencing, as needed. A total of 551 patients with chronic obstructive pulmonary disease were analyzed. Among these, 40 (7.2%) had some genetic mutation, while 11 (2%) had a Pi*ZZ genotype, resulting in severe respiratory illness. The systematic evaluation of chronic obstructive pulmonary disease patients revealed that screening is an effective method to diagnose alpha-1-antitrypsin deficiency. Early diagnosis may facilitate smoking cessation and initiation of treatment to maintain lung function.

Keywords: AAT, COPD, Severe respiratory illness, Immunonephelometry, SERPINA1

Introduction

Alpha-1-antitrypsin (AAT) is a glycoprotein produced primarily in hepatocytes and is the main serum protease inhibitor [1, 2]. This enzyme is produced by neutrophils in response to some inflammatory stimuli and aims to destroy aggressive agents. However, since it is one of the few human enzymes capable of degrading elastic fibers, it can lead to the destruction of tissues, especially those of the alveolar walls [3, 4]. Nevertheless, AAT is considered important as it acts as an antagonist of neutrophilic enzymes and is responsible for 90% of all anti-protease activity in human serum; the remaining 10% is undertaken by α2-macroglobulin [1, 3, 5, 6]. Serum levels of AAT can be elevated following acute or chronic inflammation, infections, presence of certain neoplasms, severe burns, or during pregnancy and contraceptive use [7].

Although AAT deficiency has long been considered a rare disease, it is now identified as a prevalent genetic disease [8–12], which may have a similar or higher incidence than cystic fibrosis (affecting one in 2000 - 5000 individuals). However, it is considered to be an under-diagnosed disorder [13].

Numerous studies have suggested that the frequency of mutations varies according to the study population. In Europe, the prevalence of the Z deficient allele follows a North–South and East–West gradient, with Scandinavian countries having the highest prevalence of this mutation [14]. The increased prevalence in Northern Europe has been hypothetically attributed to the heightened occurrence of the mutation in the Viking population [15]. It is known that the ZZ genotype is practically absent in Asia and Africa, while the highest prevalence of the S allele is noted in the Iberian Peninsula [1, 14]. The population of
Latin America was greatly influenced by migration from Spain, Portugal, and Italy, and hence, these mutations may be noted in a sporadic manner in this region [16]. Recently, Blanco et al. developed maps with an inverse distance weighted (IDW)-interpolation method, providing information of Pi*Z distribution worldwide. The authors estimated a total of 91,490 Pi*ZZ in America and Caribbean, and 6162 (95% CI 3053–12,297) in Brazil, however the real scenario is unknown [17]. Brazilian population is under genetic influence from Europeans (specially Portuguese), Africans and Indians, who lived in South America before the colonization.

Deficiency of AAT can result in severe chronic obstructive pulmonary disease (COPD) in young patients, and is a poorly diagnosed condition [18]. In the United States, it is estimated that 2% of all COPD patients are AAT deficient [19]. In general, AAT deficiency should be suspected in patients with COPD with no history of smoking, with a history of early-onset COPD (< 50 years-old), or in those with a family history of AAT deficiency. The presence of emphysema in the lower lobes should also be considered [12, 13, 20]. However, certain guidelines and the World Health Organization suggest that AAT evaluation should be performed in all patients with COPD, regardless of the onset, history of smoking or radiographic imaging pattern [1, 21, 22]. The under-diagnosis of AAT deficiency is a particularly important challenge in primary care, where the largest number of patients with COPD is cared for.

The aim of this study was to evaluate whether systematic screening for AAT increases the number of patients diagnosed with AAT deficiency.

**Main text**

The project was approved by the research ethics committee of the institution (CAAE: 55174616.3.0000.5259). All patients undergoing follow-up at the COPD out-clinic were invited for AAT assessment. Blood sample was collected by pricking the distal region of a finger and allowing the blood to drop onto a filter paper (Fig. 1). The AAT levels were then assessed by immunonephelometry. In patients with AAT levels < 2.64 mg/dL, the presence of a mutation was evaluated by molecular investigation for the presence of SERPINA1 gene or by genetic sequencing, as needed.

Patients with other co-existing disorders (besides COPD) were excluded. The diagnosis of COPD was based on spirometry (forced expiratory volume at first second/forced vital capacity—FEV1/FVC < 0.70 in patients with suggestive clinical features). Patients with prior diagnosis of AAT deficiency and family history of proven AAT deficiency were also excluded.

**Respiratory function tests.** All the tests were performed using a spirometer (Vitatrace) coupled to Spiromatic

---

**Fig. 1** Preparing the dried blood spots. Blood sample was collected by pricking the distal region of a finger and allowing the blood to drop onto a filter paper. The filter paper was put in an envelope and sent to the laboratory.
software, and was based on the American Thoracic Society (ATS) 1991 criteria [23]. The predicted theoretical values were those described by Knudson et al. [24].

Statistical analysis. The variables were expressed as mean and standard deviation, as the samples showed normal behavior when evaluated by the Shapiro–Wilk test. The statistical package GraphPad 7.0 was used and \( p < 0.05 \) was considered to express statistically significant values.

Results

The data of 551 patients, including 283 (51.4%) men and 268 (48.6%) women, were analyzed. Epidemiological and functional data are presented in Table 1. It was observed that 93% patients smoked, but the smoking load was lower in patients with Z homozygosity compared to the total group of patients with COPD, and to all patients with an enzyme deficiency (4 ± 11.2 p-y, 46.5 ± 41.2 p-y, and 34.7 ± 36.9 p-y, respectively); however, the spirometric values were similar to those of other COPD patients (Table 1). There was a tendency for patients with genetic mutation to be younger than the overall group of patients with COPD, but this difference was not statistically significant.

About 7.2% patients had some genetic mutation, while 2% (11 of 551 patients) had \( \text{Pi}^*\text{ZZ} \) genotype, as presented in the study flowchart (Fig. 2). All patients with \( \text{Pi}^*\text{ZZ} \) genotype had the reduced blood levels of this enzyme confirmed. There was no statistical difference between men and women with regard to SERPINE 1 mutation.

Table 1 Demographic and spirometric data from patients included in the study

|                      | All COPD patients \( n = 551 \) | AAT deficiency \( n = 40 \) | \( \text{Pi}^*\text{ZZ} \) \( n = 11 \) | p-value |
|----------------------|---------------------------------|-----------------------------|-----------------------------------|---------|
| Male: female         | 283:268                         | 21:19                       | 4:7                               | –       |
| Age (mean ± SD)      | 65.2 ± 14.0                     | 63.2 ± 10.2                 | 60.0 ± 7.3                        | 0.19    |
| Smoking (pack-years) | 46.5 ± 41.2                     | 34.7 ± 36.9                 | 4.1 ± 11.2                        | 0.02    |
| FEV\(_1\) (% predicted) | 50.2 ± 20.6                     | 49.1 ± 20.4                 | 37.7 ± 7.9                        | 0.22    |
| FVC (% predicted)    | 76.3 ± 22.3                     | 79.4 ± 19.2                 | 78.8 ± 21.4                       | 0.75    |
| FEV\(_1\)/FVC (%)    | 50.7 ± 13.6                     | 49.0 ± 13.6                 | 41.9 ± 14.6                       | 0.18    |

The difference among the three groups was analyzed by ANOVA followed by Turkey’s multiple comparison test

COPD chronic obstructive pulmonary disease, SD standard deviation, FEV1 forced expiratory volume at first second, FVC forced vital capacity

Discussion

The systematic screening for AAT deficiency is feasible and easy to perform. The doctors began to incorporate this without any difficulties in the current study. A considerable increase in the number of patients with COPD diagnosed with genetic mutation of SERPINE 1 and enzyme deficiency was noted during the study period. In 2013, there were 3 patients with the genotype \( \text{Pi}^*\text{ZZ} \) while 3 years later, there were 40 patients with genetic mutation, and 11 of them had the \( \text{Pi}^*\text{ZZ} \) genotype. The AAT deficiency is an under-diagnosed condition and
the difficulty of including this diagnostic evaluation in patients with COPD may be a contributing factor. Thus, the routine request of an AAT dosage for all patients with COPD increases the chances of diagnosing this condition. It is interesting to note that some patients with AAT deficiency were of similar age compared to other COPD patients. In addition, smoking was common throughout the group, including those with the enzyme deficiency. However, the patients with enzyme deficiency had smoked lesser prior to developing the respiratory disease. Of the 40 patients with genetic mutation, 2 were still smokers and discontinued after the mutation was identified. This demonstrates that the knowledge of this characteristic may be a factor that influences smoking cessation.

The AAT replacement was advised only for patients with homozygous Z allele. Currently, of the 11 patients diagnosed with Pi*ZZ genotype, 9 are undergoing the replacement and 2 are awaiting the purchase of the enzyme. Hepatic transaminases and bilirubin levels in patients with severe disease were normal in 10 patients. An increase in transaminases and gamma GT was noted in one patient who was an alcoholic, and is being followed-up.

The screening of other family members with a mutation, especially children, can help prevent the onset of respiratory symptoms. Until now, we have been able to evaluate 27 family members (parents, siblings, and children) of patients with AAT deficiency. Among these, 9 individuals with genetic mutation of SERPINA 1 were diagnosed, with Pi*MZ genotype in 5, Pi*ZZ in 2, and Pi*MS and Pi*SZ genotype in 1 individual each. All these individuals are being evaluated for pulmonary and hepatic function. None of the patients with the Pi*ZZ genotype had a history of smoking, but both had respiratory symptoms and one was being treated for asthma. Currently, they are receiving enzyme replacement therapy.

Our data demonstrated that >7% patients with COPD attending our service had SERPINA 1 mutation, and 11 patients (2% of patients with COPD) had a severe AAT deficiency. Two factors may be contributing to this high percentage of patients with enzyme deficiency. The first is that the study was conducted in a tertiary referral service that treats patients with serious illnesses. Thus, the outcomes may not reflect that of a general group of patients with COPD, since it is based on the percentage of patients with advanced disease, many of whom use supplemental therapy with oxygen. Secondly, the Brazilian population is represented to a large extent by European immigrants, especially Portuguese and Italian, who have a high prevalence of AAT deficiency. Although Z allele is not so prevalent among Portuguese and Italian population, the prevalence of the S allele is high in the Iberian Peninsula [14].

This study did not aim to assess the prevalence of AAT deficiency in the population, but to verify whether the implementation of the routine screening is feasible in public service setting in Brazil. The systematic evaluation of the patients was shown to be effective enough to be recommended as a screening method. Thus, the authors suggest that AAT screening should be performed in all patients with COPD regardless of age, smoking history, gender, or onset of respiratory symptoms. Early diagnosis facilitates smoking cessation and can help initiate changes in order to maintain lung function. In some cases, replacement therapy may be advised.

This study confirms that systematic screening of AAT deficiency among COPD patients increases the chances of diagnosing patients with mutations in the SERPINA1 gene.

This information is important for counseling on smoking cessation as well as for considering replacement therapy in cases of severe AAT deficiency. The methodology used was simple and feasible.

Limitation
The study was performed in a single center, which receives patients with serious illnesses. Although it is not an unpublished study, this study reinforces the data reported, especially for the region of Latin America, local with little data regarding the AAT deficiency.

Abbreviations
AAT: alpha-1-antitrypsin; COPD: chronic obstructive pulmonary disease.

Authors’ contributions
CHC: contributions to conception and design, personnel coordinator and writing. AJNF, RMFMS, TFC, VOM, and MP: contribution to acquisition of data and revising the manuscript critically. RLR: Critical contribution to analysis and interpretation of data. All authors read and approved the final manuscript.

Author details
1 Chest Department, State University of Rio de Janeiro (UERJ), Av. Marechal Rondon, 381, São Francisco Xavier, Rio de Janeiro, RJ 20950-000, Brazil. 2 Chest Department, State University of Rio de Janeiro (UERJ), Av. Vinte e Otto de Setembro, 77, Vila Isabel, Rio de Janeiro, RJ 20551-030, Brazil.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All the data supporting the results are provided in the manuscript.

Consent to publish
Not applicable.

Ethics approval and consent to participate
The project was approved by the research ethics committee of the institution and patients signed an informed consent form.
Funding
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 December 2018  Accepted: 31 December 2018
Published online: 10 January 2019

References
1. Menga G, Miravitlles M, Blanco I, Echazarreta AL, Rossi SE, Sorroche PB, et al. Normativas de diagnóstico y tratamiento del déficit de alfa-1 antitripsina. Rev Am Med Resp. 2014;34(1):28–46.
2. Contreras J, Pérez J. Deficiencia de alfa-1antitripsina. Medicina. 2009;14(3):268–77.
3. Serra HG, Bertuzzo CS, Pereira MC, Rossi CL, Pinto JW, Paschoal IA. Determination of alpha 1-antitrypsin levels and of the presence of S and Z alleles in a population of patients with chronic respiratory symptoms. J Bras Pneumol. 2008;34(12):1019–25.
4. Vecchiola CA, Ramírez MA, Villagrán TA, Serrano HC, Liberona TL, Sáez SC, et al. Intratracheal instillation of elastase in the rat: electrophoretic changes of alpha-1 antitrypsin in bronchoalveolar lavage fluid. Rev Chil Enferm Respir. 2008;24(1):7–14.
5. Stocks JW, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, et al. Pharmacokinetic comparability of Prolastin®C to Prolastin® in alpha1-antitrypsin deficiency: a randomised study. BMC Pharmacol Toxicol. 2010. https://doi.org/10.1186/1472-6904-10-13.
6. Camelier AA, Winter DH, Jardim JR, Barboza CEG, Cukier A, Miravitlles M. Alpha-1 antitrypsin deficiency: diagnosis and treatment. J Bras Pneumol. 2008;34(7):514–27.
7. Vidal R, Blanco I, Casas F, Jardí R, Miravitlles M. Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency. Arch Bronconeumol. 2006;42(12):645–59.
8. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for α1-antitrypsin deficiency. JAMA. 1988;260(9):1259–64.
9. Hatipoglu U, Stoller JK. Alpha-1-antitrypsin deficiency. Clin Chest Med. 2016;37(3):487–504.
10. Zilmer LR, Russo R, Manzano BM, Iwanaga I, Nascimento OA, Souza AAL, et al. Validation and development of an immunonephelometric assay for the determination of alpha-1 antitrypsin levels in dried blood spots from patients with COPD. J Bras Pneumol. 2013;39(5):547–54.
11. Hutsebaut J, Janssens W, Louis R, Willersinn F, Stephenne X, Sokal E, et al. Activity of the alpha-1 antitrypsin deficiency registry in belgium. COPD. 2015;12(1):10–4.
12. Costa CA, Santos C. Alpha-1 antitrypsin deficiency. The experience of the Hospital of Pulido Valente with the therapy of replacement. Rev Port Pneumol. 2009;15(3):473–82.
13. Camelier AA, Winter DH, Jardim JR, Barboza CEG, Cukier A, Miravitlles M. Alpha-1 antitrypsin deficiency: diagnosis and treatment. J Bras Pneumol. 2008;34(7):514–27.
14. Lara B. COPD and alpha-1 antitrypsin deficiency. Arch Bronconeumol. 2010;46(S4):2–8.
15. Gauvain C, Mornex JF, Pison C, Civileier A, Balduczky M, Pujazon MC, et al. Health-related quality of life in patients with alpha1 antitrypsin deficiency: the French experience. COPD. 2015;12(5):46–51.
16. Luisetti M, Seersholm N. Alpha 1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004;59(2):164–9.
17. Blanco I, Bueno F, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, et al. Alpha-1 antitrypsin Pi*z gene frequency and Pi*ZZ genotype number worldwide: an update. Int J COPD. 2017;12:561–9.
18. Paulwells RA, Busit AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.
19. Franciosi AN, McCarthy C, McElvaney NG. The efficacy and safety of inhaled human α1-antitrypsin in people with α-1 antitrypsin deficiency-related emphysema. Expert Rev Respir Med. 2015;9(2):143–51.
20. Casas F, Blanco I, Martínez MT, Bustamante A, Miravitlles M, Cadenas S, et al. Indications for active case searches and intravenous alpha-1 antitrypsin treatment for patients with alpha-1 antitrypsin deficiency chronic pulmonary obstructive disease: an update. Arch Bronconeumol. 2015;51(4):185–92.
21. McElvaney NG. Diagnosing α1-antitrypsin deficiency: how to improve the current algorithm. Eur Respir Rev. 2015;24(133):52–7.
22. Chrostoowska-Wynimko J. The national alpha-1 antitrypsin deficiency registry in poland. COPD. 2015;12(5):22–6.
23. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202–18.
24. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1985;127:725–34.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions